Cargando…

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the anti-SARS-CoV-2 antibody levels, anti-spike (S)-immunoglobulin G (IgG) and anti-nucleocapsid (N)-IgG, and the neutralization activity of IgG antibody in COVID‑19‑convalesce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuchiya, Kiyoto, Maeda, Kenji, Matsuda, Kouki, Takamatsu, Yuki, Kinoshita, Noriko, Kutsuna, Satoshi, Hayashida, Tsunefusa, Gatanaga, Hiroyuki, Ohmagari, Norio, Oka, Shinichi, Mitsuya, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869318/ https://www.ncbi.nlm.nih.gov/pubmed/36690803 http://dx.doi.org/10.1038/s41598-023-28591-3

Ejemplares similares

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
por: Inada, Makoto, et al.
Publicado: (2023)

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors
por: Hayashida, Tsunefusa, et al.
Publicado: (2017)

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
por: Hattori, Shin-ichiro, et al.
Publicado: (2018)

SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism
por: Tsuchiya, Kiyoto, et al.
Publicado: (2013)

Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
por: Inada, Makoto, et al.
Publicado: (2021)

Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C–induced HIV latency reversal
por: Matsuda, Kouki, et al.
Publicado: (2019)

Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study
por: Nishijima, Takeshi, et al.
Publicado: (2015)

Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
por: Kutsuna, Satoshi, et al.
Publicado: (2021)

Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination
por: Okumura, Nobumasa, et al.
Publicado: (2022)

The second molecular epidemiological study of HIV infection in Mongolia between 2010 and 2016
por: Jagdagsuren, Davaalkham, et al.
Publicado: (2017)

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies
por: Noda, Kenta, et al.
Publicado: (2021)

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals
por: Terada, Mari, et al.
Publicado: (2023)

Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia
por: Sato, Lubna, et al.
Publicado: (2021)

Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022)

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)
por: Tomita, Noriko, et al.
Publicado: (2022)

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators
por: Matsuda, Kouki, et al.
Publicado: (2021)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Residual and Late Onset Symptoms Appeared in a Patient with Severe Fever with Thrombocytopenia in a Convalescence Stage
por: Kanda, Kohei, et al.
Publicado: (2021)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection
por: Shimada, Takayuki, et al.
Publicado: (2017)

Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis
por: Okahara, Koki, et al.
Publicado: (2017)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19
por: Miyazato, Yusuke, et al.
Publicado: (2022)

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
por: Inada, Makoto, et al.
Publicado: (2022)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved
por: Suzuki, Tetsuya, et al.
Publicado: (2023)

No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity
por: Nomoto, Hidetoshi, et al.
Publicado: (2021)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools
por: Kober, Christina, et al.
Publicado: (2022)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
por: Matsuda, Kouki, et al.
Publicado: (2021)

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1
por: Kawashima, Akira, et al.
Publicado: (2023)

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
por: Saito, Sho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_em6d7722v87ehg6fr0peeuv6i3